Loading company
Standard Biotools Inc.
LAB · Nasdaq · ·
Next earnings: November 3, 2026
$0.71-1.5%Sep 29 close
- 1M
- +11.2%
- 6M
- -22.5%
- 1Y
- -45.1%
- 5Y
- -89.2%
LAB · Nasdaq · ·
Next earnings: November 3, 2026
$0.71-1.5%Sep 29 close
Standard Biotools Inc. is scheduled to report next on November 3, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $20.1M | $21.8M | -7.62% |
| Profit | -$26.8M | -$33.5M | +20.03% |
| Profit per share | -$0.07 | -$0.09 | +22.22% |
| Free Cash Flow | -$10.7M | -$22.6M | +52.76% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
“We remain on track to close our merger with Treeline Biosciences in 2026, with our previously filed registration statement on Form S-4, our agreement to divest our Mass Cytometry business, and Illumina’s early buyout of contingent payments for $30 million from its acquisition of SomaLogic,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
Standard BioTools, Inc. (NASDAQ: LAB), is committed to setting the new standard in the life science tools industry through strategic consolidation, best-in-class operations and a world-class management team. The Company's established portfolio includes essential, standardized next-generation solutions designed to help biomedical researchers develop better therapeutics faster. For Research Use Only. Not for use in diagnostic procedures. Limited Use Label License and other terms may apply: standardbio.com/legal/terms-and-conditions/ . Patent and License Information: standardbio.com/legal/notices . Trademarks: standardbio.com/legal/trademarks . Any other trademarks are the sole property of their respective owners.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Standard Biotools Inc.’s Item 2.02 8-K filed August 5, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Standard Biotools Inc. has no earnings call transcript available.